Dinesh has built the clinical development group from the ground up, advancing three monoclonal antibodies (mAbs) into the clinic, including two in immunology and one in infectious disease.

Before joining Generate, Dinesh served as associate vice president in quantitative pharmacology within oncology early development at Merck. During his 10 years at Merck, Dinesh played a significant part in the early oncology dose finding and registration of KEYTRUDA™ for melanoma, non-small cell lung cancer (NSCLC) and multiple other cancer indications including the first tumor agnostic biomarker (e.g microsatellite instability-high or MSI-hi) approval for cancer using a basket trial design. Dinesh is considered a global expert in his field and has extensive drug development and regulatory experience with multiple modalities such as mAbs, antibody-drug conjugates, oncolytic viruses, bispecifics and cancer vaccines and has played a significant part in multiple oncology programs in early and late development. He has also been an opinion leader in the field of oncology dose finding and model informed drug development and presented at multiple FDA-AACR workshops and an invited speaker at the Oncology Center of Excellence at the FDA.

Earlier in his career, Dinesh held several leadership and scientific roles at Eli Lilly and Company for 15 years and led the pharmacokinetics/pharmacodynamics (PK/PD) Group in the United Kingdom from preclinical to late development across several therapeutic areas.

Dinesh has published more than 50 peer-reviewed papers and received his Ph.D. from the University of Manchester, United Kingdom, in the field of Population PK/PD in 1997.

Gevorg is a cross-disciplinary thinker whose scientific contributions span computer science, biophysics, and molecular biology. His research at Dartmouth College—where he held faculty appointments in computer science, biological sciences, and chemistry—focused on uncovering the principles that link protein sequence, structure, and function. This work led to foundational advances in data-driven protein modeling and design, ultimately laying the scientific groundwork for Generate.

Motivated by the belief that therapeutic discovery could be reimagined through machine learning and programmable biology, Gevorg co-founded Generate in partnership with Flagship Pioneering. The company embodies his conviction that the future of medicine lies in systematically generating, rather than searching for, new drugs.

He holds bachelor’s degrees in computer science and biochemistry, a PhD from the Massachusetts Institute of Technology, and completed postdoctoral training at the University of Pennsylvania. Gevorg received tenure at Dartmouth in 2017.

He has authored over 50 peer-reviewed publications in leading journals including Nature, Science, and PNAS, and has received recognition from the Alfred P. Sloan Foundation, NIH, NSF, and the American Cancer Society.

Before joining Generate, Beth served as the senior vice president and chief people officer at Tripadvisor for more than seven years. In this role, she was responsible for leading a global team of approximately 130 employees in more than 20 countries. Previously, Beth served as senior vice president of global human resources at Nuance Communications, as well as vice president and head of human resources at Sanofi’s Boston hub, where she provided HR support to 6,500 employees for Genzyme, Sanofi and Sanofi Pasteur, as well as remote field teams. She also served as vice president of human resources for Genzyme, where she worked for more than a decade before the company was acquired by Sanofi in 2011.

Beth is a part-time venture advisor at SemperVirens Venture Capital, and remains a board member of the Tripadvisor Foundation. In March 2023, she was named one of the Transform 10, recognizing the 10 most inspirational executive leaders leading transformation across their areas of influence and moving the world forward.

Beth graduated from Cornell University with a Bachelor of Arts degree in English.

Most recently, Daria was the vice president of infectious disease and vaccines and chief scientific officer of the Merck Cambridge Research site. Over her 30 year career at Merck, she held various positions of increasing responsibility within both the research and medical affairs organizations, managing cross-functional research teams covering antibiotic, antiviral and vaccine research, neuroscience discovery and innovative platform development teams. She led teams to discover and develop multiple drugs that have been approved, including antivirals for HIV, hepatitis C, and cytomegalovirus, as well as anti-bacterials. Notably, Daria led research efforts that identified the first-in-class HIV integrase inhibitor, which won the 2008 Prix Galien award.

Over the course of her esteemed career, Dr. Hazuda has received numerous awards and contributed to over 200 peer-reviewed publications.

Daria trained as a biochemist at the State University of New York at Stony Brook, and went on to complete a postdoctoral research fellowship in the department of immunology at Smith Kline, now known as GSK.

Most recently, Aarif served as chief scientific officer and head of research and development at Scribe Therapeutics, where he led platform development, biology discovery, and translational research for a CasX-based genome editing and epigenetic silencing platform, with an internal focus on cardiometabolic disease. Prior to his experience at Scribe, he was head of drug development and chief medical officer at Calico Life Sciences, where he helped transform the organization into a clinical-stage company, overseeing multiple investigational new drug and clinical trial application filings and advancing a pipeline of programs across immuno-oncology, neurodegeneration, and kidney disease. Earlier in his career, Aarif spent seven years at Amgen, where he founded and led the cardiometabolic disorders therapeutic area and contributed to the discovery and advancement of several novel clinical candidates, including programs now in late-stage development.

Aarif is a board‑certified physician with training in internal medicine and cardiology. He earned his BSE in chemical engineering from Princeton University and both his MD and MBA from Columbia University. He has held academic appointments at The University of Texas MD Anderson Cancer Center and Stanford University and has authored numerous peer‑reviewed publications.

Most recently, Laurie served as vice president of research and development, transplant and immunology at CSL Behring, where she led global clinical development programs and supported the office of the CMO, overseeing various drug candidate programs in the field of solid organ and hematopoietic stem cell transplantation, immunology and nephrology. Laurie also developed novel patient recruitment and regulatory strategies to support the advancement of late-stage clinical development programs.

Prior to her role at CSL Behring, she spent 12 years at GlaxoSmithKline (GSK). At GSK, Laurie guided respiratory and allergy candidates through late-stage development, including the TRELEGY ELLIPTA asthma program from Phase 2 through approval. She also played a key role in the design and execution of numerous Phase 2, 3 and 4 studies, including a large pediatric safety trial in asthma.

Laurie is a board-certified physician in pediatrics and allergy and immunology. She is a graduate of the University of Notre Dame and obtained her M.D. from the Ohio State University College of Medicine. Laurie completed a fellowship in allergy and immunology at Duke University Medical Center, where she subsequently joined the faculty in pediatrics and conducted research on primary immune deficiency syndromes and bone marrow transplantation in the neonatal period.

Before joining Generate, Sean was General Counsel and Senior Vice President at the leading healthcare company Baxter International Inc. Under his leadership, Sean successfully oversaw the legal, compliance, and government affairs for several key projects, including the largest acquisition in Baxter’s history, Hillrom, Inc.

Before that role, he was General Counsel, Senior Vice President and Secretary at Apollo Education Group. Previously, he was Vice President for Commercial Law and Corporate Law at Amgen and Vice President and Deputy General Counsel for Litigation at Fresenius Medical Care North America. Earlier in his career, Sean was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases.

Sean graduated summa cum laude from the University of Michigan with a bachelor’s degree in History and graduated magna cum laude from the Harvard Law School.

Since his appointment in 2021, Mike has helped lead Generate:Biomedicines’ growth as it pioneers Generative Biology®. During his tenure, the company completed its Series B and C financing rounds and raised more than $750 million prior to its initial public offering. In 2026, Generate completed its IPO, raising approximately $400 million to advance its platform and pipeline. These funding milestones have enabled continued investment in the company’s generative AI platform and a growing pipeline of protein therapeutics, including five clinical-stage molecules and multiple additional preclinical programs.

Mike has also been instrumental in forging significant partnerships with leading institutions, laying a strong foundation for future advancement. For example, in 2022, the company announced a collaboration with Amgen focused on developing protein therapies, which was later expanded in January 2024. Additionally, in 2023, Generate:Biomedicines announced strategic collaborations with the MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center, which aim to harness their respective strengths in specialized medical research and treatment modalities to deliver novel therapeutics in oncology and CAR-T cells respectively.

Before joining Generate:Biomedicines, Mike held several key leadership positions at Merck & Co., Inc. As Chief Marketing Officer, he was responsible for the Global Marketing and Brand Strategy of a diverse portfolio encompassing innovative medicines and vaccines, generating over $40 billion in revenue. His previous roles at Merck & Co. include serving as President of Global Vaccines and managing the company’s operations in Sweden and the UK.

In addition to his executive role at Generate:Biomedicines, Mike serves on the boards of Expedition Medicines, Harbinger Health, and PPG Industries. At PPG Industries, he is a member of the Audit Committee and the Sustainability and Innovation Committee.

Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.

Before joining Generate, Sahm spent several years in biotech leading Business Development and Strategy activities as a Chief Business Officer, particularly leading complex platform focused collaborations across multiple technologies and therapeutic areas. Prior to this, Sahm worked at Merck & Co. for seven years as a leader across business development, investor relations and strategy functions involving extensive commercial drug development experience. During this time, he established and led the global strategy and operations team for Merck’s growing oncology organization and served as interim Vice President and Global Product Leader for Merck’s portfolio of HPV Vaccines. Before Merck, Sahm was a strategy consultant with McKinsey & Company in Australia. Sahm holds a B.S. in chemical engineering from the University of New South Wales in Sydney and an MBA from Columbia Business School in New York City.

In 2024, Jason was named one of Boston Business Journal’s CFOs of the Year, recognizing his leadership in steering Generate:Biomedicines’ financial strategy through complex market conditions, securing one of the largest Series C raises of 2023 with $281 million, and fostering transformative collaborations with MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, and an expanded agreement with Amgen.

Before joining Generate, Jason was at Goldman Sachs for 20 years, where he became a Managing Director and Partner. Most recently, he was based in London and co-managed healthcare investment banking for Europe, the Middle East and Africa. Previously, he served as the Global Head of Healthcare Mergers and Acquisitions. Over his career, he has completed more than 75 merger and acquisition and financing transactions valued at more than $400 billion.

Jason graduated magna cum laude from Brown University with a bachelor’s of science degree in chemistry. He attended the Johns Hopkins University School of Medicine. After medical school, he completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction. He continued his education at Yale Law School, where he earned his juris doctor degree and was editor-in-chief of the Yale Journal of Health Policy, Law, and Ethics.

At Flagship Pioneering, which he founded in 2000, Noubar has created an enterprise where entrepreneurially minded scientists invent seemingly unreasonable solutions to challenges facing human health and sustainability. They begin by asking “What if?” and iterate toward the unexpected answer “It turns out,” resulting in the creation of first-in-category companies with significant impact. Flagship has fostered the development of more than 100 scientific ventures resulting in $30 billion in aggregate value, thousands of patents and patent applications, and more than 50 drugs in clinical development.

During his career as inventor, entrepreneur, and CEO, Noubar has co-founded and helped build over 40 life sciences and technology startups. Prior to founding Flagship Pioneering, Noubar was the founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he became senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

He serves on the boards of a number of public and private Flagship companies, including Moderna (NASDAQ: MRNA), where he is chairman and Rubius Therapeutics (NASDAQ: RUBY). Previously, he was a member of the founding team, director, and investor in highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millenium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen).

Noubar entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He has written numerous scientific publications and has been granted approximately 100 patents. He is a lecturer at Harvard Business School, and from 2000 to 2016 was a senior lecturer at MIT’s Sloan School of Management. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy.

Noubar’s commitment to improving the human condition through science and business goes hand in hand with social investments and a global humanitarian initiative. Together with his partners in Flagship, he has launched philanthropic projects including the IDeA Foundation, UWC Dilijan School, 100 LIVES, and the Aurora Prize for Awakening Humanity, which seeks to raise awareness of the world’s most pressing humanitarian problems. Noubar is a member of the Corporation of MIT (the Institute’s governing body) and a member of the board of overseers for the Boston Symphony Orchestra.

Noubar was born in Beirut to Armenian parents in 1962, did his undergraduate work at McGill University in Montreal, and completed his PhD in biochemical engineering at MIT in 1987. A passionate advocate of the contributions of immigrants to economic and scientific progress, Noubar received the Golden Door Award in 2017 from the International Institute of New England, in honor of his outstanding contributions to American society as a U.S citizen of foreign birth. He was also awarded a Great Immigrant honor from the Carnegie Corporation in 2016, received a Technology Pioneer award from the World Economic Forum in 2012, and was presented with the Ellis Island Medal of Honor in 2008.

Frances received the Nobel Prize in Chemistry (2018) for pioneering directed enzyme evolution; she has used those methods to create enzymes for alternative energy, chemicals, and medicine. Frances received the Charles Stark Draper Prize of the U.S. National Academy of Engineering in 2011, the U.S. National Medal of Technology and Innovation from President Obama in 2013, and the Millennium Technology Prize in 2016. She has been elected to all three of the U.S. National Academies of Science, Medicine, and Engineering. She was appointed by Pope Francis to the Pontifical Academy of Sciences in 2019.

Co-inventor on 58 issued U.S. patents and active in technology transfer, Frances co-founded Gevo, Inc., in 2005 to make fuels and chemicals from renewable resources; Provivi, Inc., in 2014 to develop non-toxic modes of agricultural pest control; and Aralez, Inc., in 2019 to develop sustainable biocatalytic processes for producing medicines and chemicals. Frances received her BS in mechanical and aerospace engineering from Princeton University and her PhD in Chemical engineering from the University of California, Berkeley. She chairs the Advisory Panel of the David and Lucile Packard Foundation Fellowships in Science and Engineering and is a trustee of the Gordon Research Conferences.

Stéphane has served as Moderna’s chief executive officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as chief executive officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as managing director for Belgium and as executive director of global manufacturing strategy and supply chain. Prior to his work at Lilly, Stéphane served as Asia-Pacific sales and marketing director for bioMérieux.

Stéphane currently serves on the board of directors of Generate:Biomedicines and Qiagen N.V., and he previously served on the boards of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is a venture partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Stéphane holds a master of engineering degree from École Centrale Paris (ECP), a master’s of science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.

From 2000 to 2009, Marsha held several executive leadership roles at Millennium Pharmaceuticals, including chief financial officer, senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development and strategy. She helped lead Millennium to profitability and played a central role in the company’s $8.8 billion acquisition by Takeda Pharmaceutical Company in 2008.

Earlier in her career, she served as vice president of corporate development and strategy at Genzyme Corporation and as vice president and director at Arthur D. Little.

Marsha has previously served on the boards of Alnylam Pharmaceuticals, Momenta Pharmaceuticals, Ironwood Pharmaceuticals, Cyclerion Therapeutics, Forma Therapeutics, and Syros Pharmaceuticals.

She earned a Bachelor of Science in Pharmacy from West Virginia University and an MBA from Northeastern University.

Jane spent over 20 years working at the Yale Investment Office, the Harvard Management Company and then Wellesley College in various roles managing their endowments and investments. In 2008, she returned to Harvard as Chief Executive Officer of the management company, where she was responsible for the university’s approximately $37 billion global endowment and related assets for six years. Under her leadership, Harvard became the first university endowment to join the PRI, a United Nations-supported network of investors committed to promoting sustainable investments by incorporating environmental, social and governance factors into investment decision-making.

Jane has received many honors, including the 100 Women in Hedge Funds 2007 Leadership Award for her “talent, ethics and passion, which help define the industry’s standard of excellence.” She was also named one of Forbes 100 Most Powerful Women in 2008 and 2009. Jane received her bachelor of arts degree from Yale College and her master’s of business administration from the Yale School of Management.

Since his appointment in 2021, Mike has helped lead Generate:Biomedicines’ growth as it pioneers Generative Biology®. During his tenure, the company completed its Series B and C financing rounds and raised more than $750 million prior to its initial public offering. In 2026, Generate completed its IPO, raising approximately $400 million to advance its platform and pipeline. These funding milestones have enabled continued investment in the company’s generative AI platform and a growing pipeline of protein therapeutics, including five clinical-stage molecules and multiple additional preclinical programs.

Mike has also been instrumental in forging significant partnerships with leading institutions, laying a strong foundation for future advancement. For example, in 2022, the company announced a collaboration with Amgen focused on developing protein therapies, which was later expanded in January 2024. Additionally, in 2023, Generate:Biomedicines announced strategic collaborations with the MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center, which aim to harness their respective strengths in specialized medical research and treatment modalities to deliver novel therapeutics in oncology and CAR-T cells respectively.

Before joining Generate:Biomedicines, Mike held several key leadership positions at Merck & Co., Inc. As Chief Marketing Officer, he was responsible for the Global Marketing and Brand Strategy of a diverse portfolio encompassing innovative medicines and vaccines, generating over $40 billion in revenue. His previous roles at Merck & Co. include serving as President of Global Vaccines and managing the company’s operations in Sweden and the UK.

In addition to his executive role at Generate:Biomedicines, Mike serves on the boards of Expedition Medicines, Harbinger Health, and PPG Industries. At PPG Industries, he is a member of the Audit Committee and the Sustainability and Innovation Committee.

Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.

Paul leads all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship’s relationships with Limited Partners as well as strategic and financial investors. He also plays a key role on Flagship’s senior leadership team, helping drive value, impact, and effectiveness across the organization.

Paul brings over 35 years of experience in banking, pharma and biotech, as well as in mergers and acquisitions (M&A), corporate strategy, and organizational leadership. He has worked across multiple sectors and geographies, built and managed several multi-billion-dollar businesses, and led teams of several thousand employees.

Prior to joining Flagship, Paul was a Corporate Officer, member of the Company Leadership Team, and served as Senior Vice President, Strategy and Corporate Development for Thermo Fisher Scientific. In this capacity he held a number of enterprise-level operating roles, including having responsibility for Corporate Strategy, Corporate Development, Strategic Capital, Integration Management, Corporate Social Responsibility, and Government Relations. He previously served as Co-Chairman of the Global Mergers and Acquisitions Group for Goldman Sachs & Co. and served on the firm’s Partnership Committee and the Investment Banking Senior Leadership Council. Prior to Goldman Sachs, Paul held senior positions at Barclays Group Plc where he served as Chairman and Head of Global M&A, subsequently adding responsibilities as Co-Head of Corporate Finance. He was previously an investment banker at Lehman Brothers in several senior leadership positions, ultimately serving as Chairman and Head of Global M&A. Earlier in his career, Parker held positions at other financial institutions, including J.P. Morgan & Co.

Paul previously served as a Board member of The Clorox Company from 2020-2024.

He earned an MBA with distinction from Harvard Business School and a bachelor’s degree in international studies from the University of North Carolina at Chapel Hill.

Prior to Syros, Nancy was Chief Medical Officer at Millennium Pharmaceuticals and Vice President of Clinical Development at Biogen. At Millennium, Nancy oversaw the successful development of VELCADE to treat multiple myeloma and mantle cell lymphoma, NINLARO to treat multiple myeloma and ENTYVIO to treat inflammatory bowel disease. At Biogen, she played a central role in developing AVONEX and TYSABRI for multiple sclerosis.

Nancy started her career as an assistant professor at Harvard Medical School and Massachusetts General Hospital (MGH). She trained in medicine and neurology at MGH, received an M.D. from the University of Pennsylvania, and a B.A. in biology from Princeton. She currently serves as a director of the board of Alltrna (private company), the supervisory board of Bayer AG (BAYR) and the Damon Runyon Cancer Research Foundation. She previously served as a director of Syros (NASDAQ: SYRS), Seagen (NASDAQ: SGEN; acquired by Pfizer in 2023), Evelo (NASDAQ: EVLO) and Arqule (NASDAQ: ARQL; acquired by Merck in 2020).

Previously, Rupert served as Executive Vice President and President, Research for Bristol Myers Squibb (BMS). He joined BMS with its acquisition of Celgene in 2019. In this role, he led Research, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also worked closely with Business Development to identify external sources of innovation. In addition, he served as the executive sponsor of the Organization for Latino Achievement (OLA) People and Business Resource Group and the Bristol Myers Squibb STEM Council.

Rupert joined BMS from Celgene, where he served as president of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent 10 years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.

Rupert graduated from Oxford University in the United Kingdom with degrees in physiological sciences (M.A.), clinical medicine (B.M., B.Ch.) and a Doctor of Philosophy (DPhil) in molecular immunology. He is an elected fellow of the Royal College of Physicians.